Cutaneous T cell lymphoma and graft-versus-host disease: A comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells

Clinical Immunology

Volumn 133, Issue 3, 2009, Pages 303-313

  Rao, Vidar ^a   Saunes, Marit ^b   Jørstad, Størker ^b   Moen, Torolf ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cutaneous T cell lymphoma; Extracorporeal photochemotherapy; Forkhead box p3; Graft versus host disease; Mycosis fungoides; Regulatory T cells

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOSPORIN; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DOWN REGULATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPHOMA CELL; MALE; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHOTOPHERESIS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 70449129742     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.08.016     Document Type: Article

References (54)

1. Edelson R., et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N. Engl. J. Med. 316 6 (1987) 297-303
2. Greinix H.T., et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 96 7 (2000) 2426-2431
3. Barr M.L., et al. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin. Transplant. 14 2 (2000) 162-166
4. Lehrer M.S., et al. Successful reversal of severe refractory cardiac allograft rejection by photopheresis. J. Heart Lung Transplant. 20 11 (2001) 1233-1236
5. Dall'Amico R., et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis. J. Am. Soc. Nephrol. 9 1 (1998) 121-127
6. Knobler R.M., et al. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J. Am. Acad. Dermatol. 54 5 (2006) 793-799
7. Faresjo M.K., et al. The immunological effect of photopheresis in children with newly diagnosed type 1 diabetes. Pediatr. Res. 58 3 (2005) 459-466
8. Enomoto D.N., et al. Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy. Photochem. Photobiol. 65 1 (1997) 177-180
9. Rao V., et al. In vitro experiments demonstrate that monocytes and dendritic cells are rendered apoptotic by extracorporeal photochemotherapy, but exhibit unaffected surviving and maturing capacity after 30 Gy gamma irradiation. Scand. J. Immunol. 68 6 (2008) 645-651
10. Billingham R.E. Reactions of grafts against their hosts. Science 130 (1959) 947-953
11. Fujita S., et al. Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells. Blood 110 10 (2007) 3793-3803
12. Girardi M., McNiff J.M., and Heald P.W. Extracorporeal photochemotherapy in human and murine graft-versus-host disease. J. Dermatol. Sci. 19 2 (1999) 106-113
13. Child F.J., et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant. 23 9 (1999) 881-887
14. Alcindor T., et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 98 5 (2001) 1622-1625
15. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 12 1 Suppl 2 (2006) 7-12
16. Lamioni A., et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 79 7 (2005) 846-850
17. Zic J.A. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol. Ther. 16 4 (2003) 337-346
18. Rook A.H., et al. Photopheresis: clinical applications and mechanism of action. J. Investig. Dermatol. Symp. Proc. 4 1 (1999) 85-90
19. Disis M.L., Bernhard H., and Jaffee E.M. Use of tumour-responsive T cells as cancer treatment. Lancet 373 9664 (2009) 673-683
20. Sakaguchi S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 3 (1995) 1151-1164
21. O'Garra A., and Vieira P. Regulatory T cells and mechanisms of immune system control. Nat. Med. 10 8 (2004) 801-805
22. Fontenot J.D., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 3 (2005) 329-341
23. Yi H., et al. The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell Mol. Immunol. 3 3 (2006) 189-195
24. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 4 (2003) 330-336
25. Bennett C.L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27 1 (2001) 20-21
26. Allan S.E., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19 4 (2007) 345-354
27. Walker M.R., et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J. Clin. Invest. 112 9 (2003) 1437-1443
28. Chattopadhyay S., Chakraborty N.G., and Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol. Immunother. 54 12 (2005) 1153-1161
29. Terabe M., and Berzofsky J.A. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16 2 (2004) 157-162
30. Huehn J., et al. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 199 3 (2004) 303-313
31. Stephens G.L., Andersson J., and Shevach E.M. Distinct subsets of FoxP3+ regulatory T cells participate in the control of immune responses. J. Immunol. 178 11 (2007) 6901-6911
32. Zhao D., et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 112 5 (2008) 2129-2138
33. Borsellino G., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110 4 (2007) 1225-1232
34. Vonderheid E.C., et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J. Am. Acad. Dermatol. 46 1 (2002) 95-106
35. Russell-Jones R. World Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology. J. Am. Acad. Dermatol. 48 1 (2003) 93-102
36. Berger C.L., et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 105 4 (2005) 1640-1647
37. Tiemessen M.M., et al. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J. Invest. Dermatol. 126 10 (2006) 2217-2223
38. Lucas M., et al. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J. Immunol. 171 5 (2003) 2610-2615
39. Fadok V.A., et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101 4 (1998) 890-898
40. Huynh M.L., Fadok V.A., and Henson P.M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109 1 (2002) 41-50
41. Voll R.E., et al. Immunosuppressive effects of apoptotic cells. Nature 390 6658 (1997) 350-351
42. Chen X., et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110 10 (2007) 3804-3813
43. Carlson M.J., et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113 6 (2009) 1365-1374
44. Banham A.H. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol. 27 12 (2006) 541-544
45. Sakaguchi S., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182 (2001) 18-32
46. Tuovinen H., et al. Thymic production of human FOXP3+ regulatory T cells is stable but does not correlate with peripheral FOXP3 expression. Immunol. Lett. 117 2 (2008) 146-153
47. Klemke C.D., et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 20 6 (2006) 1123-1129
48. Clark F.J., et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 103 6 (2004) 2410-2416
49. Zorn E., et al. Reduced frequency of FOXP3+CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 8 (2005) 2903-2911
50. Bladon J., and Taylor P. Extracorporeal photopheresis normalizes some lymphocyte subsets (including T regulatory cells) in chronic graft-versus-host-disease. Ther. Apher. Dial. 12 4 (2008) 311-318
51. Biagi E., et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 84 1 (2007) 31-39
52. Gjerdrum L.M., et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 21 12 (2007) 2512-2518
53. Di Biaso I., et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation 87 9 (2009) 1422-1425
54. Bunn Jr. P.A., and Lamberg S.I. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat. Rep. 63 4 (1979) 725-728